ICON: Eosinophil disorders

World Allergy Organization Journal

Volumn 5, Issue 12, 2012, Pages 174-181

  Valent, Peter ^a   Klion, Amy D ^b   Rosenwasser, Lanny J ^c   Arock, Michel ^d   Bochner, Bruce S ^e   Butterfield, Joseph H ^f   Gotlib, Jason ^g   Haferlach, Torsten ^h   Hellmann, Andrzej ⁱ   Horny, Hans Peter ^j   Leiferman, Kristin M ^k   Metzgeroth, Georgia ^l   Matsumoto, Kenji ^m   Reiter, Andreas ^l   Roufosse, Florence ⁿ   Rothenberg, Marc E ^o   Simon, Hans Uwe ^p   Sotlar, Karl ⁱ   Vandenberghe, Peter ^q   Weller, Peter F ^r   Gleich, Gerald J ^k   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d Ecole Normale Superieure de Cachan   (France)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g STANFORD CANCER INSTITUTE   (United States)

^h MLL MUNICH LEUKEMIA LABORATORY   (Germany)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^j UNIVERSITY OF MUNICH   (Germany)

^k UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m Natl Childrens Med Res Ctr   (Japan)

ⁿ ERASME HOSPITAL   (Belgium)

^o CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^p UNIVERSITY OF BERN   (Switzerland)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^r HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Classification; Eosinophil disorders; Global consensus; Hypereosinophilic syndrome (HES)

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; HYDROXYUREA; IMATINIB; MEPOLIZUMAB; MIDOSTAURIN; NILOTINIB; PONATINIB; SORAFENIB; BIOLOGICAL MARKER; DASATINIB; GLUCOCORTICOID; IMMUNOGLOBULIN M; INTERLEUKIN 5; TROPONIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; EOSINOPHILIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; LOW DRUG DOSE; LYMPHATIC LEUKEMIA; NOMENCLATURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; ALLERGIC DISEASE; ANGIONEUROTIC EDEMA; BONE MARROW; BONE MARROW CELL; CARDIOVASCULAR MAGNETIC RESONANCE; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIA MYALGIA SYNDROME; GENE REARRANGEMENT; GLEICH SYNDROME; HEALTH CARE NEED; HYPER IGE SYNDROME; IMMUNOLOGY; INFLAMMATION; LYMPHOID CELL; MULTIPLE ORGAN FAILURE; OMENN SYNDROME; PARANEOPLASTIC SYNDROME; PDGFRA GENE; PDGFRB GENE; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; REACTIVE HYPEREOSINOPHILIC SYNDROME; TREATMENT INDICATION; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 85064746421     PISSN: 19394551     EISSN: None     Source Type: Journal    
DOI: 10.1097/wox.0b013e31827f4192     Document Type: Article

References (88)

1. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med. 1968;68:1220-1229.
2. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1-27.
3. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759-2779.
4. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med. 2003;54:169-184.
5. Wilkins HJ, Crane MM, Copeland K, Williams WV. Hypereosinophilic syndrome: an update. Am J Hematol. 2005;80:148-157.
6. Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol. 2007;119:1291-1300.
7. Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 2010;126:45-49.
8. Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev. 2009;23:157-165.
9. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130:607-612.
10. Bain BJ, Pierre R, Imbert M, Vardiman JW, Brunning RD, et al. Chronic eosinophilic leukemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Vol 1. Lyon, France: IARC Press; 2001:29-31.
11. Bain BJ, Gilliland DG, Vardiman JW, Horny HP. Chronic eosinophilic leukemia, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al, eds. World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Vol 2. Lyon, France: IARC Press; 2008:51-53.
12. Bain BJ, Gilliland DG, Horny HP, Vardiman JW. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al, eds. World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Vol 2. Lyon, France: IARC Press; 2008:68-73.
13. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14-22.
14. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (1) chronic eosinophilic leukemias. Leukemia. 2004;18:734-742.
15. Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol. 2008;87:1-10.
16. Cross NC, Reiter A. Fibroblast growth factor receptor and plateletderived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol. 2008;119:199-206.
17. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008;22:1999-2010.
18. Tefferi A. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med. 2009;13:215-237.
19. Kay AB. The eosinophil in infection diseases. J Infect Dis. 1974;129:606-613.
20. Capron M. Eosinophils and parasites. Ann Parasitol Hum Comp. 1991;66:41-45.
21. Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011;36:6-11.
22. Kargili A, Bavbek N, Kaya A, Kosxar A, Karaaslan Y. Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases. Rheumatol Int. 2004;24:321-324.
23. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133:468-492.
24. Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, et al. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987;1:643-647.
25. Kato M, Kephart GM, Talley NJ, et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Record. 1998;252:418-425.
26. Noguchi H, Kephart GM, Colby TV, Gleich GJ. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol. 1992;140:521-528.
27. Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Immunol Allergy Clin North Am. 2007;27:529-549.
28. Gotlib J, Cross NC, Gilliland DG. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol. 2006;19:535-569.
29. Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2007;27:377-388.
30. Valent P, Gleich GJ, Reiter A, Roufosse F, Weller PF, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012;5:157-176.
31. Wimazal F, Germing U, Kundi M, Noesslinger T, Blum S, et al. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer. 2010;116:2372-2381.
32. Pardanani A, Reeder T, Li CY, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res. 2003;27:883-885.
33. Böhm A, Födinger M, Wimazal F, Haas OA, Mayerhofer M, et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol. 2007;120:192-199.
34. Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114:3769-3772.
35. Takai K, Sanada M. Hypereosinophilic syndrome evolving to acute lymphoblastic leukemia. Int J Hematol. 1991;54:231-239.
36. Scales JW, McMichael A. Persistent peripheral eosinophilia and cutaneous non-Hodgkin's lymphoma: a case report and review of the literature. Cutis. 2001;67:67-70.
37. Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:389-413.
38. Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13) (p11;q12) myeloproliferative syndrome. Blood. 1998;92:1735-1742.
39. Lowe D, Jorizzo J, Hutt MS. Tumour-associated eosinophilia: a review. J Clin Pathol. 1981;34:1343-1348.
40. Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008;38:709-750.
41. Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341:1112-1120.
42. Roufosse F, Schandené L, Sibille C, Willard-Gallo K, Kennes B, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol. 2000;109:540-548.
43. Freymond N, Kahn JE, Legrand F, Renneville A, Cordier JF, et al. Clonal expansion of T cells in patients with eosinophilic lung disease. Allergy. 2011;66:1506-1508.
44. Gleich GJ, Schroeter AL, Marcoux JP, Sachs MI, O'Connell EJ, et al. Episodic angioedema associated with eosinophilia. N Engl J Med. 1984;310:1621-1626.
45. Butterfield JH, Leiferman KM, Abrams J, et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood. 1992;79:688-692.
46. Gross WL. Churg-Strauss syndrome: update on recent developments. Curr Opin Rheumatol. 2002;14:11-14.
47. Keogh KA, Specks U. Churg-Strauss syndrome. Semin Respir Crit Care Med. 2006;27:148-157.
48. Pagnoux C, Guillevin L. Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol. 2010;22:21-28.
49. Silver RM. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1992;4:851-856.
50. Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1995;7:560-567.
51. Belongia EA, Gleich GJ. The eosinophilia-myalgia syndrome revisited. J Rheumatol. 1996;23:1682-1685.
52. Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol. 2010;126:179-181.
53. Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, et al. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcriptdresults of Polish multicentre study. Hematol Oncol. 2010;28:93-97.
54. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol. 2000;105:651-663.
55. Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am. 2007;27:357-375.
56. Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, et al. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol. 1989;19:701-705.
57. Kita H, Weiler DA, Abu-Ghazaleh R, Sanderson CJ, Gleich GJ. Release of granule proteins from eosinophils cultured with IL-5. J Immunol. 1992;149:629-635.
58. Yousefi S, Blaser K, Simon HU. Activation of signaling pathways and prevention of apoptosis by cytokines in eosinophils. Int Arch Allergy Immunol. 1997;112:9-12.
59. Kahn JE, Dutoit-Lefevre V, Duban-Deweer S, Chafey P, Pottiez G, et al. Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. J Proteome Res. 2011;10:1468-1480.
60. Weller PF. Eicosanoids, cytokines and other mediators elaborated by eosinophils. In: Makino S, Fukuda T, eds. Eosinophils: Biological and Clinical Aspects. Boca Raton, FL: CRC Press; 1993:125-154.
61. Moqbel R, Levi-Schaffer F Kay AB. Cytokine generation by eosinophils. J Allergy Clin Immunol. 1994;94:1183-1188.
62. Moqbel R, Ying S, Barkans J, et al. Identification of messenger RNA for IL-4 in human eosinophils with granule localisation and release of the translated product. J Immunol. 1995;155:4939-4947.
63. Kay AB, Barata L, Meng Q, Durham SR, Ying S. Eosinophils and eosinophil-associated cytokines in allergic inflammation. Int Arch Allergy Immunol. 1997;113:196-199.
64. Walsh GM. Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci. 1999;36:453-496.
65. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, et al. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol. 1989;142:4428-4434.
66. Hamann KJ, Barker RL, Ten RM, Gleich GJ. The molecular biology of eosinophil granule proteins. Int Arch Allergy Appl Immunol. 1991;94:202-209.
67. Plager DA, Stuart S, Gleich GJ. Human eosinophil granule major basic protein and its novel homolog. Allergy. 1998;53:33-40.
68. Benezet-Mazuecos J, de la Fuente A, Marcos-Alberca P, Farre J. Loeffler endocarditis: what have we learned? Am J Hematol. 2007;82:861-862.
69. Ogbogu PU, Rosing DR, Horne MK III. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:457-475.
70. Kleinfeldt T, Nienaber CA, Kische S, Akin I, Turan RG, et al. Cardiac manifestation of the hypereosinophilic syndrome: new insights. Clin Res Cardiol. 2010;99:419-427.
71. Jeong YJ, Kim KI, Seo IJ, Lee CH, Lee KN, et al. Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. Radiographics. 2007;27:617-637.
72. Simon D, Wardlaw A, Rothenberg ME. Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol. 2010;126:3-13.
73. Louis R, Sele J, Henket M, Cataldo D, Bettiol J, et al. Sputum eosinophil count in a large population of patients with mild to moderate steroidnaïve asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy. 2002;57:907-912.
74. Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012:129:S9-23.
75. Leiferman KM, Gleich GJ, Peters MS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:415-441.
76. Zuo L, Rothenberg ME. Gastrointestinal eosinophilia. Immunol Allergy Clin North Am. 2007;27:443-455.
77. Lee J, Dierkhising R, Wu TT, Alexander J, Weiler C. Eosinophilic gastrointestinal disorders (EGID) with peripheral eosinophilia: a retrospective review at Mayo Clinic. Dig Dis Sci. 2011;56:3254-3261.
78. Klion A. Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med. 2009;60:293-306.
79. Klion AD. How I treat hypereosinophilic syndromes. Blood. 2009;114:3736-3741.
80. Roufosse F, Weller P. Practical approach to the patient with marked hypereosinophilia. J Allergy Clin Immunol. 2010;126:39-44.
81. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215-1228.
82. Roufosse F, de Lavareille A, Schandené L, Cogan E, Georgelas A, et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol. 2010;126:828-835.
83. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487.
84. Cools J, De Angelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
85. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101:3391-3397.
86. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005;114:52-60.
87. Reiter A, Grimwade D, Cross NC. Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. Haematologica. 2007;92:1153-1158.
88. Metzgeroth G, Walz C, Erben P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008;143:707-715.